3.4 Polycythemia & Erythrocytosis Classification

Polycythemia & Erythrocytosis Classification

Erythrocytosis (or polycythemia) is defined as an abnormal elevation in red blood cell parameters: hemoglobin ($>16.5\text{ g/dL}$ in men, $>16.0\text{ g/dL}$ in women), hematocrit ($>49%$ in men, $>48%$ in women), or red blood cell count ($>5.8 \times 10^{12}/\text{L}$ in men, $>5.2 \times 10^{12}/\text{L}$ in women). Precise clinical classification is essential to distinguish benign hemoconcentration from life-threatening clonal myeloproliferative neoplasms and occult neoplasms.

                         CLASSIFICATION OF ERYTHROCYTOSIS
                                        |
        +-------------------------------+-------------------------------+
        |                                                               |
RELATIVE ERYTHROCYTOSIS                                         ABSOLUTE ERYTHROCYTOSIS
- Normal Red Cell Mass                                          - True Increased Red Cell Mass
- Decreased Plasma Volume                                       - Elevated Hb / Hct / RBC Count
- Dehydration, Gaisböck Syndrome                                                |
                                                +-------------------------------+-------------------------------+
                                                |                                                               |
                                        PRIMARY POLYCYTHEMIA                                            SECONDARY ERYTHROCYTOSIS
                                        (Polycythemia Vera - MPN)                                       - Elevated / Normal EPO
                                        - LOW / SUPPRESSED EPO                                          - JAK2 Mutation NEGATIVE
                                        - JAK2 V617F (>95%) / Exon 12                                                   |
                                        - Panmyelosis (RBC + WBC + Plt)                 +-------------------------------+-------------------------------+
                                                                                        |                                                               |
                                                                                PHYSIOLOGICALLY APPROPRIATE                     INAPPROPRIATE (AUTONOMOUS)
                                                                                (Hypoxia-Driven EPO Elevation)                  (Non-Hypoxic EPO Secretion)
                                                                                - Altitude, COPD, Cyanotic Heart                - Renal Cell Carcinoma (RCC)
                                                                                - Smoker's Polycythemia (COHb)                  - Hepatocellular Carcinoma
                                                                                - High-Affinity Hemoglobins (Low p50)           - Polycystic Kidney Disease

---

1. Relative vs. Absolute Erythrocytosis

Relative Erythrocytosis (Spurious / Apparent)

• Pathophysiology: Total red blood cell mass (RCM) is completely normal, but plasma volume is markedly decreased (contracted), resulting in artifactual hemoconcentration.
• Etiologies:
  1. Acute Dehydration: Severe vomiting, diarrhea, excessive diaphoresis, severe burns, or aggressive diuretic therapy.
  2. Gaisböck Syndrome (Stress Erythrocytosis / Pseudopolycythemia): Characteristically observed in middle-aged, hypertensive, obese, anxious men who smoke heavily; associated with chronic contracted plasma volume and elevated hematocrit without true red cell mass expansion.

Absolute Erythrocytosis

• Pathophysiology: True, biological expansion of the total circulating red blood cell mass exceeding $125%$ of predicted normal. Absolute erythrocytosis is subclassified into Primary (autonomous stem cell proliferation) and Secondary (growth factor / EPO driven).

---

2. Primary Polycythemia: Polycythemia Vera (PV)

Molecular Pathogenesis & The JAK2 Mutation

Polycythemia Vera is a clonal Myeloproliferative Neoplasm (MPN) originating in a multipotent hematopoietic stem cell. The hallmark molecular driver is a somatic mutation in the Janus Kinase 2 (JAK2) gene:

• $JAK2\text{ V617F}$ Point Mutation (Exon 14): Present in $>95%$ of PV cases. A substitution of valine for phenylalanine at codon 617 in the JH2 pseudokinase (regulatory) domain abolishes auto-inhibition, locking the JAK2 tyrosine kinase into a constitutively active, ligand-independent firing state.
• $JAK2\text{ Exon 12}$ Mutations: Present in $3\text{--}4%$ of PV cases (particularly in younger patients presenting with isolated erythrocytosis without prominent leukocytosis or thrombocytosis).
• Signal Transduction: Constitutive JAK2 phosphorylation persistently activates downstream STAT5, PI3K/Akt, and MAPK signaling pathways, driving uncontrolled erythroid, myeloid, and megakaryocytic proliferation independent of exogenous erythropoietin.

JAK2 V617F Mutation in JH2 Regulatory Domain
  --> Loss of Auto-Inhibitory Control
  --> Constitutive Tyrosine Kinase Phosphorylation (Ligand-Independent)
  --> Continuous Activation of STAT5, PI3K/Akt, and MAPK Pathways
  --> Panmyelosis in Bone Marrow
  --> Hyperviscosity, Thrombosis, & Massive Systemic Red Cell Expansion
  --> Negative Feedback Loops Suppress Renal EPO Secretion (LOW SERUM EPO)

WHO Diagnostic Criteria for Polycythemia Vera

Diagnosis requires meeting all 3 major criteria, or the first 2 major criteria plus the minor criterion:

MAJOR CRITERIA:
1. Hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women), OR
   Hematocrit >49% (men) or >48% (women), OR
   Increased red cell mass (>25% above mean normal predicted)
2. Bone marrow biopsy showing hypercellularity for age with trilineage growth
   (panmyelosis: prominent erythroid, granulocytic, and pleomorphic megakaryocytic proliferation)
3. Presence of JAK2 V617F or JAK2 exon 12 mutation

MINOR CRITERION:
- Subnormal / Suppressed Serum Erythropoietin (EPO) level

Clinical and Laboratory Hallmarks of PV

• Suppressed Serum EPO: Because erythroid expansion is driven autonomously by mutant JAK2 signaling, physiological negative feedback suppresses renal EPO synthesis, resulting in subnormal or undetectable serum EPO ($<4\text{ mU/mL}$). This is the single most important biochemical distinction from secondary polycythemia.
• Panmyelosis on CBC: Elevated RBC count ($6.0\text{--}10.0 \times 10^{12}/\text{L}$), leukocytosis ($12.0\text{--}25.0 \times 10^9/\text{L}$ with neutrophilia and basophilia), and thrombocytosis ($450\text{--}1000 \times 10^9/\text{L}$).
• Leukocyte Alkaline Phosphatase (LAP / NAP Score): Characteristically elevated ($>100$, often $150\text{--}250$), reflecting mature granulocytic activation (in contrast to Chronic Myeloid Leukemia where LAP is low/zero).
• Clinical Manifestations:
  • Hyperviscosity Syndrome: Headache, dizziness, visual scotomas, tinnitus, and angina.
  • Aquagenic Pruritus: Severe, intractable itching after contact with warm water (without a rash), mediated by mast cell and basophil degranulation.
  • Thrombosis (Arterial and Venous): Leading cause of morbidity; includes stroke, myocardial infarction, and deep vein thrombosis at unusual sites (Budd-Chiari syndrome, mesenteric thrombosis).
  • Splenomegaly: Present in $\approx 70%$ of patients due to extramedullary hematopoiesis.
  • Plethoric "Ruddy" Complexion & Erythromelalgia: Burning pain and erythema in the hands and feet caused by microvascular platelet occlusion.

---

3. Secondary Erythrocytosis

Secondary erythrocytosis is driven by elevated or inappropriately normal serum erythropoietin (EPO) acting on normal, non-clonal hematopoietic progenitors. The $JAK2$ mutation is negative, and panmyelosis is absent (WBC and platelets are normal).

                       SECONDARY ERYTHROCYTOSIS PATHWAYS
                                       |
        +------------------------------+------------------------------+
        |                                                             |
PHYSIOLOGICALLY APPROPRIATE                                   PHYSIOLOGICALLY INAPPROPRIATE
(Hypoxia-Driven EPO Production)                               (Autonomous EPO Hypersecretion)
        |                                                             |
Renal Hypoxia Stabilizes HIF-1alpha                           Tumor / Tissue Overproduces EPO
  --> Transcribes Renal EPO Gene                                Directly Without Hypoxia
  --> High Serum EPO Stimulates Marrow                          --> High Serum EPO Stimulates Marrow

1. Physiologically Appropriate (Hypoxia-Driven Secondary Erythrocytosis)

Renal interstitial peritubular fibroblasts monitor tissue oxygen tension ($pO_2$). Under hypoxic conditions, prolyl hydroxylases cannot hydroxylate Hypoxia-Inducible Factor 1$\alpha$ ($HIF\text{-}1\alpha$). Non-hydroxylated $HIF\text{-}1\alpha$ escapes proteasomal degradation, accumulates, heterodimerizes with $HIF\text{-}1\beta$, translocates to the nucleus, and activates transcription of the erythropoietin (EPO) gene.

• High Altitude Acclimatization: Low ambient atmospheric $pO_2$.
• Chronic Pulmonary Diseases: Severe Chronic Obstructive Pulmonary Disease (COPD), diffuse interstitial pulmonary fibrosis, obesity-hypoventilation syndrome, and obstructive sleep apnea (OSA).
• Cyanotic Congenital Heart Disease: Right-to-left shunts (e.g., Tetralogy of Fallot, Eisenmenger syndrome).
• Smoker's Polycythemia (Carboxyhemoglobinemia): Cigarette smoke contains carbon monoxide ($CO$), which binds to hemoglobin with an affinity 210 times greater than oxygen, generating carboxyhemoglobin (COHb). COHb cannot bind oxygen and allosterically locks the remaining three heme groups in the high-affinity relaxed (R) state, shifting the oxygen-dissociation curve to the left. This causes profound tissue hypoxia and compensatory EPO elevation, combined with nicotine-induced plasma volume contraction.
• High-Affinity Hemoglobin Variants: Globin chain mutations (e.g., Hb Chesapeake, Hb Yakima, Hb Malmö, Hb Montefiore) alter the $\alpha_1\beta_2$ contact interface, preventing transition from the high-affinity R state to the low-affinity T state. The oxygen-dissociation curve is severely shifted to the left, characterized by a markedly decreased $P_{50}$ (the partial pressure of $O_2$ at which hemoglobin is 50% saturated; normal $P_{50} \approx 26.6\text{ mmHg}$, in high-affinity variants $P_{50} < 18\text{ mmHg}$). The kidney senses pseudohypoxia and hypersecretes EPO.
• Congenital Methemoglobinemia: Oxidation of iron to $Fe^{3+}$ prevents $O_2$ transport and left-shifts the ODC.

2. Physiologically Inappropriate (Autonomous EPO Hypersecretion)

Renal or extra-renal tissues autonomously produce EPO independent of physiological oxygen tension:

• Renal Neoplasms & Structural Lesions:
  • Renal Cell Carcinoma (RCC): Classic EPO-secreting malignancy.
  • Polycystic Kidney Disease (PKD) and Hydronephrosis: Expanding cysts compress adjacent peritubular capillaries, generating localized, false renal ischemia that triggers massive focal EPO secretion despite normal systemic oxygenation.
  • Renal Artery Stenosis: Unilateral renal hypoperfusion drives excessive EPO synthesis.
• Extra-Renal Autonomous Tumors:
  • Hepatocellular Carcinoma (HCC) (~5–10% secrete EPO).
  • Cerebellar Hemangioblastoma (vascular tumor producing EPO).
  • Uterine Leiomyomas (Fibroids) (large fibroids producing autonomous erythropoietin).
  • Pheochromocytoma and Adrenal Cortical Tumors.
• Exogenous Administration: Recombinant human erythropoietin (rhEPO/darbepoetin) abuse (blood doping in athletes) or androgen/testosterone therapy (stimulates renal EPO synthesis and direct bone marrow erythropoiesis).

---

4. Comprehensive Differential Diagnostic Comparison